Through Tumor Related Microbial Biomarkers
Micronoma liquid biopsy technology interrogates the microbial signal to detect and predict cancer with clinical-grade accuracy.
Saving patient lives with a minimally-invasive, cancer screening test.
International oncology, microbiome and drug discovery expertise synergize to guide unique early cancer detection startup SAN DIEGO, Dec. 9, 2020 /PRNewswire/ -- Micronoma, the first cancer detection biotech company that uses signals from the tumor-related microbiome...
Innovative early cancer detection company establishes headquarters and adds three key executive positions San Diego, Calif. (November 5, 2020). Micronoma, an early-stage cancer detection biotech company seeking to develop and commercialize a minimally-invasive, unique...
Humans and Microbes
Humans and microbes co-exist in a mutual beneficial relationship in our bodies. Microbes can be found naturally not only in our stools, but also in our mouths, tissues and even our blood.
The microbiome is the community of all the microbes—bacteria, fungi, protozoa and viruses—that live on and inside the human body.
Microbes and Cancer
Microbes are now known to be found in human tissues, including cancer tissues. Micronoma is going a step further and looking at microbial signatures that would be predictive of a tumor in circulating blood.
Micronoma can detect and distinguish microbes in blood and predict if a patient is cancer free or presenting a specific cancer type.
draw to collect samples
research, discovery, and
NEXT GEN SEQUENCING
Using genomic sequencing to
pipelines to decipher and
New cancer cases
worldwide each year
Cancer deaths each year,
most preventable with
Global liquid biopsy market
forecast for 2023*
Better Approach to Liquid Biopsy
A liquid biopsy is a test done on a sample of blood to look for circulating tumor cells (CTC) or DNA that is shed from the tumor. Liquid biopsies may help find cancer at an early stage.
However, CTCs and ctDNA are scarce, fragile, and heterogenous, which means they are difficult to detect and may be missed. Additionally, they may not be cancer-specific, as various cancers can share many types of alterations.
Traditional liquid biopsies focus on all tumor DNA in the blood to identify the small mutation markers linked to the cancer. Present at often less than 0.1%, ensuring the capture of these rare biomarkers is a difficult task. At Micronoma, we focus on the microbial DNA. With noise and complexity removed, established microbial signatures are enriched and more evident.
Pharm. D., Ph.D.
Co-Founder, Board Member, President and Chief Executive Officer
Co-Founder, Board Member, Chief Analytic Officer, Oncobiota™ Co-Inventor
Rob Knight, Ph.D.
Co-Founder and Scientific Advisory Board, Oncobiota™ Co-Inventor
Eddie Adams, Ph.D.
Chief Scientific Officer
Chief Operating Officer
Magda Marquet, Ph.D.
Chairman of the Board; Co-Founder, Ajinomoto Althea & AltheaDx
Scientific Advisory Board
Martin J. Blaser, M.D.
Chairman, Professor of Medicine and Pathology and Director of the Center for Advanced Biotechnology and Medicine, and holds the Henry Rutgers Chair of the Human Microbiome at Rutgers University.
Leena Das-Young, Pharm. D.
C-suite executive for biopharma in oncology, infectious disease, liquid biopsy, and product development in complex disease and precision medicine settings, including executive roles at both Pfizer and Guardant Health.
Ravid Straussman, M.D., Ph.D.
Principal Investigator at the Weizmann Institute where his research is focused on understanding the roles of the tumor microenvironment and the tumor microbiome on resistance to cytotoxic, targeted, and immune-mediated anti-cancer therapies.